Patents by Inventor Veit Hornung

Veit Hornung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210147831
    Abstract: The invention provides a cell library for use in detecting protein expression comprising a plurality of cells, wherein each cell comprises a polynucleotide sequence encoding a detectable marker integrated into the genome of the cell in frame with a protein coding gene selected from a set of target genes, wherein the library comprises more than one cell tagged at each target gene, as well as a cell library for use in detecting protein interactions between a protein of interest and a set of target proteins and a cell library for use in detecting protein modifications. The invention also provides methods of constructing a cell library for use in proteomics, as well as methods for sequencing integration sites of a donor sequence inserted into the genome of a cell. Also provided are systems for analysis of proteins in a cell and kits comprising vectors for tagging a population of cells and for performing proteomics studies.
    Type: Application
    Filed: April 26, 2019
    Publication date: May 20, 2021
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Jonathan Leo Schmid-Burgk, Veit Hornung
  • Patent number: 10238682
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universit├Ąt Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20180313843
    Abstract: The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 1, 2018
    Inventors: Oliver Till KEPPLER, Jindrich CINATL, Constanze SCHNEIDER, Hanna-Mari BALDAUF, Sarah-Marie SCHWARZ, Hubert SERVE, Thomas OELLERICH, Gerd GEISSLINGER, Veit HORNUNG
  • Patent number: 10059938
    Abstract: The present invention is directed to methods and kits for gene analysis. The methods of the invention comprise the steps of providing nucleic acid; synthesis of a single-stranded DNA that is complementary to said nucleic acid molecule by contacting the nucleic acid with a DNA polymerase, a primer and a mixture of dNTPs under conditions that allow the generation of the DNA, wherein the primer comprises a target-complementary region and wherein the dNTP mixture comprises dATP, dGTP, dCTP, dTTP and dUTP; cleaving the DNA 5? to dU sites by (i) contacting the DNA with an uracil deglycosylase to generate a basic sites at positions of dUTP incorporation in the DNA; and (ii) contacting the DNA with an apurinic/apyrimidinic (AP) endonuclease; contacting the DNA comprising at its 5?-end the nucleotide sequence of the primer with a ssDNA ligase to circularize the DNA; and sequencing the circularized cDNA. The kits comprise the components necessary to perform the methods of the invention.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 28, 2018
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
    Inventors: Veit Hornung, Jonathan Schmid-Burgk
  • Patent number: 9381208
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: July 5, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universit├Ąt
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20160122818
    Abstract: The present invention is directed to methods and kits for gene analysis. The methods of the invention comprise the steps of providing nucleic acid; synthesis of a single-stranded DNA that is complementary to said nucleic acid molecule by contacting the nucleic acid with a DNA polymerase, a primer and a mixture of dNTPs under conditions that allow the generation of the DNA, wherein the primer comprises a target-complementary region and wherein the dNTP mixture comprises dATP, dGTP, dCTP, dTTP and dUTP; cleaving the DNA 5? to dU sites by (i) contacting the DNA with an uracil deglycosylase to generate a basic sites at positions of dUTP incorporation in the DNA; and (ii) contacting the DNA with an apurinic/apyrimidinic (AP) endonuclease; contacting the DNA comprising at its 5?-end the nucleotide sequence of the primer with a ssDNA ligase to circularize the DNA; and sequencing the circularized cDNA. The kits comprise the components necessary to perform the methods of the invention.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Inventors: Veit Hornung, Jonathan Schmid-Burgk
  • Publication number: 20160051573
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Application
    Filed: November 9, 2015
    Publication date: February 25, 2016
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 8815503
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 26, 2014
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 8334101
    Abstract: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 18, 2012
    Assignee: University of Massachusetts
    Inventors: Eicke Latz, Veit Hornung, Katherine A. Fitzgerald
  • Publication number: 20120288476
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 15, 2012
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20120121551
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-?-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 17, 2012
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20120045461
    Abstract: Tis invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.
    Type: Application
    Filed: July 8, 2011
    Publication date: February 23, 2012
    Inventors: Gunther Hartmann, Antonin de Fougerolles, Veit Hornung, Stefan Endres
  • Patent number: 8076068
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-?-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: December 13, 2011
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 8003619
    Abstract: This invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: August 23, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gunther Hartmann, Antonin de Fougerolles, Veit Hornung, Stefan Endres
  • Publication number: 20100178272
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Application
    Filed: August 8, 2007
    Publication date: July 15, 2010
    Applicant: Klinische Pharmakologie
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20100150938
    Abstract: Methods of treating an inflammatory disorder and inhibiting inflammation by administering an inhibitor of a pH-activated protease are provided.
    Type: Application
    Filed: July 2, 2009
    Publication date: June 17, 2010
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Eicke Latz, Douglas Golenbock, Kenneth L. Rock, Veit Hornung, Annett Halle
  • Publication number: 20100120894
    Abstract: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.
    Type: Application
    Filed: September 25, 2009
    Publication date: May 13, 2010
    Inventors: Eicke Latz, Veit Hornung, Katherine A. Fitzgerald
  • Publication number: 20090169529
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-?-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Application
    Filed: September 14, 2006
    Publication date: July 2, 2009
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20090111765
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Application
    Filed: September 14, 2006
    Publication date: April 30, 2009
    Inventors: Gunther Hartmann, Veit Hornung
  • Publication number: 20060217330
    Abstract: This invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.
    Type: Application
    Filed: December 9, 2005
    Publication date: September 28, 2006
    Inventors: Gunther Hartmann, Antonin Fougerolles, Veit Hornung, Stefan Endres